MS4A1 and B-cell chronic lymphocytic leukemia: The activity of idelalisib is largely non-overlapping with that of anti-CD20 antibodies (except for effects on phagocytic activity of microphages); thus, combination therapy with idelalisib and rituximab is found to be synergistic for patients with CLL [165].